Mirikizumab Real World Protocol

This real-world study is collecting data on how mirikizumab — a newer biologic drug that targets the IL-23 immune pathway — performs in patients with moderate to severe ulcerative colitis (UC) in everyday clinical practice (outside of a controlled clinical trial). The goal is to understand how well it works across a diverse patient population. **You may be eligible if...** - You are 18 or older - You have been diagnosed with ulcerative colitis based on standard clinical, imaging, endoscopic, and tissue criteria - You have recently started mirikizumab (within the past 2 weeks) or are about to start it as a standard-of-care treatment - Your treating center expects to follow you for at least 12 months **You may NOT be eligible if...** - You are not starting mirikizumab as part of your routine care - You do not meet diagnostic criteria for UC - You are unwilling to be followed for the study duration Talk to your doctor to see if this trial is right for you.